Formycon AG (CHIX:FYBD) FFO


CHIX:FYBD Formycon AG CHIX:FYBD
64 GF Score
Price €63.30
GF Value €121.24
! 5 Warning Signs
View Full Analysis

What is Formycon AG FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:FYBD
64GF Score
Formycon AG CHIX:FYBD
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 47.8% below its estimated GF Value™ of €121.24.

Key valuation signals for CHIX:FYBD:

  • FFO:
  • GF Value™: €121.24 vs. price of €63.30 (47.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
64GF Score

Get the complete analysis for CHIX:FYBD

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€121.24
GF Value